Moyamoya DiseaseFAMESNCT07517354
Family-Based Moyamoya Susceptibility and Early Detection
An observational study of Moyamoya Disease, run by Beijing Tiantan Hospital at 1 site in China.
Trial summary
This single-center, prospective, family-based observational cohort study aims to investigate susceptibility to moyamoya disease (MMD) and to develop strategies for early screening in individuals at increased familial risk. Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Moyamoya Disease
- What is being tested?
- 5T High-Resolution MRI
- How many people
- 700 participants
- Where
- 1 siteChina
- Study dates
- 12 Nov 2024to 30 Nov 2030
- How long will I take part?
- 3 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: This is a single-center, family-based prospective observational cohort study conducted at Beijing Hospital. The study plans to enroll 700 participants, including 400 patients with moyamoya disease, 200 first-degree relatives of patients with moyamoya disease, and 100 healthy controls without a family history of moyamoya disease. The study population is designed to compare patients, unaffected first-degree relatives at familial risk, and healthy controls in order to identify early biological and imaging markers, evaluate disease susceptibility, and develop early screening strategies for high-risk populations.
Who may be able to join
- Participants must belong to 1 of the following 3 cohorts:
- Moyamoya disease cohort: diagnosed with primary moyamoya disease according to standard diagnostic criteria, with progressive stenosis or occlusion at the terminal internal carotid arteries and/or their major branches and typical collateral vessels on DSA, CTA, or MRA; newly diagnosed and previously diagnosed cases are both eligible; no age or sex restriction.
- First-degree relative cohort: first-degree blood relatives of patients with moyamoya disease, including parents, children, and siblings; no age or sex restriction; no clinical diagnosis of moyamoya disease and no history of stroke or other cerebrovascular events at enrollment; baseline MRI does not show definite moyamoya disease, although mild changes are allowed.
- Healthy control cohort: no family history of moyamoya disease; no personal history of cerebrovascular disease; no major abnormalities on physical examination or baseline screening; age and sex distribution matched as closely as possible to the moyamoya disease cohort.
Who cannot join
- Major systemic or central nervous system diseases that may interfere with study results or substantially affect survival or adherence, such as advanced malignant tumors, active tuberculosis or other serious infections, active systemic lupus erythematosus, or severe hepatic or renal dysfunction.
- Atypical cerebrovascular lesions on baseline imaging, such as widespread atherosclerotic stenosis or congenital vascular malformations.
- Inability to complete examinations or follow-up, including MRI contraindications such as non-compatible metal implants or severe claustrophobia, expected difficulty completing follow-up because of long-term relocation, poor communication access, poor adherence, or other situations judged by the investigators to make participation inappropriate.
- Pregnant women.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Beijing Hospital
Beijing, Beijing Municipality, 100730
Dong Zhang, MD, +86-13801121292, zhangdong0660@aliyun.com
About this study
Official title: The FAME Study: A Family-Based Cohort Study on Moyamoya Disease Susceptibility and Early Screening
This single-center, prospective, family-based observational cohort study aims to investigate susceptibility to moyamoya disease (MMD) and to develop strategies for early screening in individuals at increased familial risk. The study will enroll three groups: patients with MMD, their first-degree relatives, and healthy controls without a family history of MMD.
The rationale for this study is that MMD has an important genetic component, but genetic susceptibility alone does not fully explain disease onset. Current diagnosis often relies on angiographic evaluation after symptoms have already appeared. This study seeks to identify earlier, less invasive biological and imaging markers that may help detect individuals at high risk before overt clinical disease develops.
Read more
At baseline, participants will undergo collection of demographic and clinical data, vascular risk factors, neurological assessments, routine laboratory testing, and 5T high-resolution magnetic resonance imaging. Biospecimens including blood, urine, stool, saliva, and nasal swabs will be collected for multi-omics and biomarker analyses; surgically obtained tissue specimens may also be collected from patients undergoing clinically indicated surgery.
Participants in the patient and first-degree relative groups will be followed annually for 3 years, primarily by telephone or online questionnaire, with optional repeat 5T MRI during follow-up. The primary objective is to identify baseline biological and imaging features associated with incident MMD in first-degree relatives and to establish an interpretable early-screening framework for high-risk populations.
Read the detailed description
Moyamoya disease (MMD) is a chronic, progressive cerebrovascular disorder characterized by progressive stenosis or occlusion of the terminal internal carotid arteries and their major branches, accompanied by the development of abnormal collateral vessels. Although genetic susceptibility plays an important role in MMD, incomplete penetrance suggests that non-genetic factors, including immune, inflammatory, metabolic, microbial, and environmental influences, may also contribute to disease onset and progression. Earlier identification of high-risk individuals remains challenging because definitive diagnosis is often made only after clinical symptoms appear.
This study is an investigator-initiated, single-center, prospective, non-randomized, non-interventional observational cohort study conducted at Beijing Hospital. A total of 700 participants are planned for enrollment, including 400 patients with MMD, 200 first-degree relatives of patients with MMD, and 100 healthy controls without a family history of MMD. The overall study duration is 5 years, and the expected participation time for each participant is approximately 3 years.
The main objective is to identify early biological and imaging markers of MMD and to evaluate susceptibility in individuals with familial risk. By comparing patients, unaffected first-degree relatives, and healthy controls at baseline, and by prospectively following the relative group, the study aims to determine which baseline features are associated with future disease development and to define risk factors that may support early screening strategies. The study also seeks to generate a multimodal panel of candidate markers and to build an interpretable early warning framework for high-risk populations.
At baseline, the study will collect demographic data, family history, medical history, medication use, vascular risk factors, smoking and alcohol exposure, neurological status, physiological measures, and lifestyle information. All groups will undergo routine laboratory testing and 5T high-resolution MRI at enrollment. Biospecimens will include blood, urine, stool, saliva, and nasal swabs for analyses such as inflammatory markers, metabolomics, and microbiome profiling. For patients who undergo clinically indicated surgery, operative tissue specimens may also be collected without adding surgical risk.
Follow-up will be performed once yearly for 3 years, mainly by telephone or online questionnaire, in the patient and first-degree relative groups. Participants who are willing may return for optional repeat 5T MRI. Follow-up assessments will include new diagnosis of MMD or suspected cerebrovascular events in the relative group, disease progression in the patient group, functional outcome by modified Rankin Scale, changes in symptoms and daily activity, medication changes, and control of major risk factors. If new MMD or stroke-related events are suspected, relevant medical records and imaging data will be collected for outcome adjudication.
The primary outcomes are: (1) incident MMD during follow-up in first-degree relatives, confirmed by clinical diagnosis and imaging findings; and (2) disease progression and prognosis in patients with MMD, including recurrent stroke or transient ischemic attack, rehospitalization, repeat surgery or intervention, and functional outcome. Secondary outcomes include imaging progression, cardiovascular or cerebrovascular death and all-cause mortality, and post-stroke disability defined as modified Rankin Scale score greater than 3.
The analytical strategy will include baseline cross-sectional comparisons across the three groups and longitudinal analysis of first-degree relatives according to whether MMD develops during follow-up. Candidate biomarkers and imaging features associated with future disease onset will be evaluated and integrated into prediction models using regression-based and/or machine-learning approaches, with assessment of discrimination, calibration, and potential clinical utility for early screening.
- Conditions
- Moyamoya Disease
- Being tested
- 5T High-Resolution MRI
- Keywords
- Moyamoya Disease, Early Screening, Family-Based Cohort, Biomarkers, High-Resolution MRI, Multi-omics
- Medical subject headings
- Moyamoya Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
5T High-Resolution MRIDiagnostic test
5T high-resolution MRI will be performed in all cohorts at baseline enrollment. During follow-up, repeat 5T MRI may be performed optionally in participants who are willing to return for imaging reassessment.
| Study group | Role | What they receive |
|---|---|---|
| Moyamoya Disease Patients | Participants with moyamoya disease diagnosed according to standard imaging criteria, including newly diagnosed or previously diagnosed cases. Typical findings may be identified on DSA, CTA, or MRA. This observational cohort will undergo baseline clinical assessment, routine laboratory testing, 5T high-resolution MRI, and biospecimen collection. Planned enrollment: 400. Receives: Diagnostic Test: 5T High-Resolution MRI | |
| First-Degree Relatives of Patients With Moyamoya Disease | First-degree blood relatives of patients with moyamoya disease, including parents, children, and siblings, without a clinical diagnosis of moyamoya disease or prior cerebrovascular events at enrollment. Baseline MRI must not show definite moyamoya disease, although mild changes may be allowed. Participants will undergo baseline assessment and annual follow-up for 3 years to identify incident moyamoya disease and early risk markers. Planned enrollment: 200. Receives: Diagnostic Test: 5T High-Resolution MRI | |
| Healthy Controls | Healthy participants without a family history of moyamoya disease and without a personal history of cerebrovascular disease. Participants should have no major abnormalities on baseline screening, and age and sex distribution will be matched as closely as possible to the moyamoya disease group. This observational cohort will undergo baseline clinical assessment, routine laboratory testing, 5T high-resolution MRI, and biospecimen collection. Planned enrollment: 100. Receives: Diagnostic Test: 5T High-Resolution MRI |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incident Moyamoya Disease in First-Degree Relatives
Incident moyamoya disease occurring during follow-up in first-degree relatives of patients with moyamoya disease, confirmed by clinical diagnosis and imaging findings, including computed tomography angiography (CTA), magnetic resonance angiography (MRA), or digital subtraction angiography (DSA).
Measured: From enrollment through 3 years of follow-up
Recurrent Stroke or Transient Ischemic Attack in Participants With Moyamoya Disease
Occurrence of recurrent stroke or transient ischemic attack during follow-up in participants with moyamoya disease, confirmed by clinical evaluation and imaging findings when applicable.
Measured: From enrollment through 3 years of follow-up
Secondary outcomes (3)
Rehospitalization in Participants With Moyamoya Disease
Any rehospitalization related to moyamoya disease or its complications during follow-up in participants with moyamoya disease.
Measured: From enrollment through 3 years of follow-up
Repeat Surgery or Intervention in Participants With Moyamoya Disease
Any repeat surgical revascularization or other disease-related intervention during follow-up in participants with moyamoya disease.
Measured: From enrollment through 3 years of follow-up
Functional Outcome Assessed by Modified Rankin Scale
Functional outcome assessed using the Modified Rankin Scale, a 7-point scale ranging from 0 to 6, where 0 indicates no symptoms and 6 indicates death; higher scores indicate worse functional outcome.
Measured: At 3 years after enrollment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Apr 2026
- Study start12 Nov 2024
- Primary completion30 Nov 2027 (estimated)
- Study completion30 Nov 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Moyamoya DiseaseStudies of the same condition, open and under way.
- More trials run by Beijing Tiantan HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 700 participants (estimated)
- Target duration
- 3 Years
Sponsor and investigators
- Lead sponsor
- Beijing Tiantan Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Dong Zhang, Beijing Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07517354
- Sponsor's protocol ID
- 2026BJYYEC-KY030-01
- Acronym
- FAMES
- Status last verified
- Apr 2026
- First submitted
- 28 Mar 2026
- Last updated
- 8 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: Individual participant data sharing is currently undecided. The study involves longitudinal clinical, imaging, biospecimen, and multi-omics data from patients with moyamoya disease, first-degree relatives, and healthy controls. Any future sharing of de-identified individual participant data will depend on institutional policy, ethics committee approval, participant consent, data privacy protection, and the development of an appropriate data access mechanism.
Study at a glance
From the registry record, last updated by the sponsor on 8 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The FAME Study: A Family-Based Cohort Study on Moyamoya Disease Susceptibility and Early Screening
- ClinicalTrials.gov ID
- NCT07517354
- Acronym / sponsor ID
- FAMES / 2026BJYYEC-KY030-01
- Conditions
- Moyamoya Disease
- Keywords
- Moyamoya Disease, Early Screening, Family-Based Cohort, Biomarkers, High-Resolution MRI, Multi-omics
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 700 participants (estimated)
- Lead sponsor
- Beijing Tiantan HospitalUniversity, hospital or other
- Study start
- 12 Nov 2024 (actual)
- Primary completion
- 30 Nov 2027 (estimated)
- Study completion
- 30 Nov 2030 (estimated)
- First posted
- 8 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This single-center, prospective, family-based observational cohort study aims to investigate susceptibility to moyamoya disease (MMD) and to develop strategies for early screening in individuals at increased familial risk. The study will enroll three groups: patients with MMD, their first-degree relatives, and healthy controls without a family history of MMD.
The rationale for this study is that MMD has an important genetic component, but genetic susceptibility alone does not fully explain disease onset. Current diagnosis often relies on angiographic evaluation after symptoms have already appeared. This study seeks to identify earlier, less invasive biological and imaging markers that may help detect individuals at high risk before overt clinical disease develops.
At baseline, participants will undergo collection of demographic and clinical data, vascular risk factors, neurological assessments, routine laboratory testing, and 5T high-resolution magnetic resonance imaging. Biospecimens including blood, urine, stool, saliva, and nasal swabs will be collected for multi-omics and biomarker analyses; surgically obtained tissue specimens may also be collected from patients undergoing clinically indicated surgery.
Participants in the patient and first-degree relative groups will be followed annually for 3 years, primarily by telephone or online questionnaire, with optional repeat 5T MRI during follow-up. The primary objective is to identify baseline biological and imaging features associated with incident MMD in first-degree relatives and to establish an interpretable early-screening framework for high-risk populations.
Detailed description
Moyamoya disease (MMD) is a chronic, progressive cerebrovascular disorder characterized by progressive stenosis or occlusion of the terminal internal carotid arteries and their major branches, accompanied by the development of abnormal collateral vessels. Although genetic susceptibility plays an important role in MMD, incomplete penetrance suggests that non-genetic factors, including immune, inflammatory, metabolic, microbial, and environmental influences, may also contribute to disease onset and progression. Earlier identification of high-risk individuals remains challenging because definitive diagnosis is often made only after clinical symptoms appear.
This study is an investigator-initiated, single-center, prospective, non-randomized, non-interventional observational cohort study conducted at Beijing Hospital. A total of 700 participants are planned for enrollment, including 400 patients with MMD, 200 first-degree relatives of patients with MMD, and 100 healthy controls without a family history of MMD. The overall study duration is 5 years, and the expected participation time for each participant is approximately 3 years.
The main objective is to identify early biological and imaging markers of MMD and to evaluate susceptibility in individuals with familial risk. By comparing patients, unaffected first-degree relatives, and healthy controls at baseline, and by prospectively following the relative group, the study aims to determine which baseline features are associated with future disease development and to define risk factors that may support early screening strategies. The study also seeks to generate a multimodal panel of candidate markers and to build an interpretable early warning framework for high-risk populations.
At baseline, the study will collect demographic data, family history, medical history, medication use, vascular risk factors, smoking and alcohol exposure, neurological status, physiological measures, and lifestyle information. All groups will undergo routine laboratory testing and 5T high-resolution MRI at enrollment. Biospecimens will include blood, urine, stool, saliva, and nasal swabs for analyses such as inflammatory markers, metabolomics, and microbiome profiling. For patients who undergo clinically indicated surgery, operative tissue specimens may also be collected without adding surgical risk.
Follow-up will be performed once yearly for 3 years, mainly by telephone or online questionnaire, in the patient and first-degree relative groups. Participants who are willing may return for optional repeat 5T MRI. Follow-up assessments will include new diagnosis of MMD or suspected cerebrovascular events in the relative group, disease progression in the patient group, functional outcome by modified Rankin Scale, changes in symptoms and daily activity, medication changes, and control of major risk factors. If new MMD or stroke-related events are suspected, relevant medical records and imaging data will be collected for outcome adjudication.
The primary outcomes are: (1) incident MMD during follow-up in first-degree relatives, confirmed by clinical diagnosis and imaging findings; and (2) disease progression and prognosis in patients with MMD, including recurrent stroke or transient ischemic attack, rehospitalization, repeat surgery or intervention, and functional outcome. Secondary outcomes include imaging progression, cardiovascular or cerebrovascular death and all-cause mortality, and post-stroke disability defined as modified Rankin Scale score greater than 3.
The analytical strategy will include baseline cross-sectional comparisons across the three groups and longitudinal analysis of first-degree relatives according to whether MMD develops during follow-up. Candidate biomarkers and imaging features associated with future disease onset will be evaluated and integrated into prediction models using regression-based and/or machine-learning approaches, with assessment of discrimination, calibration, and potential clinical utility for early screening.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 3 Years
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Moyamoya Disease Patients | – | Diagnostic Test: 5T High-Resolution MRIParticipants with moyamoya disease diagnosed according to standard imaging criteria, including newly diagnosed or previously diagnosed cases. Typical findings may be identified on DSA, CTA, or MRA. This observational cohort will undergo baseline clinical assessment, routine laboratory testing, 5T high-resolution MRI, and biospecimen collection. Planned enrollment: 400. |
| First-Degree Relatives of Patients With Moyamoya Disease | – | Diagnostic Test: 5T High-Resolution MRIFirst-degree blood relatives of patients with moyamoya disease, including parents, children, and siblings, without a clinical diagnosis of moyamoya disease or prior cerebrovascular events at enrollment. Baseline MRI must not show definite moyamoya disease, although mild changes may be allowed. Participants will undergo baseline assessment and annual follow-up for 3 years to identify incident moyamoya disease and early risk markers. Planned enrollment: 200. |
| Healthy Controls | – | Diagnostic Test: 5T High-Resolution MRIHealthy participants without a family history of moyamoya disease and without a personal history of cerebrovascular disease. Participants should have no major abnormalities on baseline screening, and age and sex distribution will be matched as closely as possible to the moyamoya disease group. This observational cohort will undergo baseline clinical assessment, routine laboratory testing, 5T high-resolution MRI, and biospecimen collection. Planned enrollment: 100. |
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- This is a single-center, family-based prospective observational cohort study conducted at Beijing Hospital. The study plans to enroll 700 participants, including 400 patients with moyamoya disease, 200 first-degree relatives of patients with moyamoya disease, and 100 healthy controls without a family history of moyamoya disease. The study population is designed to compare patients, unaffected first-degree relatives at familial risk, and healthy controls in order to identify early biological and imaging markers, evaluate disease susceptibility, and develop early screening strategies for high-risk populations.
Key inclusion criteria (4 listed)
- Participants must belong to 1 of the following 3 cohorts:
- Moyamoya disease cohort: diagnosed with primary moyamoya disease according to standard diagnostic criteria, with progressive stenosis or occlusion at the terminal internal carotid arteries and/or their major branches and typical collateral vessels on DSA, CTA, or MRA; newly diagnosed and previously diagnosed cases are both eligible; no age or sex restriction.
- First-degree relative cohort: first-degree blood relatives of patients with moyamoya disease, including parents, children, and siblings; no age or sex restriction; no clinical diagnosis of moyamoya disease and no history of stroke or other cerebrovascular events at enrollment; baseline MRI does not show definite moyamoya disease, although mild changes are allowed.
- Healthy control cohort: no family history of moyamoya disease; no personal history of cerebrovascular disease; no major abnormalities on physical examination or baseline screening; age and sex distribution matched as closely as possible to the moyamoya disease cohort.
Key exclusion criteria (4 listed)
- Major systemic or central nervous system diseases that may interfere with study results or substantially affect survival or adherence, such as advanced malignant tumors, active tuberculosis or other serious infections, active systemic lupus erythematosus, or severe hepatic or renal dysfunction.
- Atypical cerebrovascular lesions on baseline imaging, such as widespread atherosclerotic stenosis or congenital vascular malformations.
- Inability to complete examinations or follow-up, including MRI contraindications such as non-compatible metal implants or severe claustrophobia, expected difficulty completing follow-up because of long-term relocation, poor communication access, poor adherence, or other situations judged by the investigators to make participation inappropriate.
- Pregnant women.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| 5T High-Resolution MRI5T high-resolution MRI will be performed in all cohorts at baseline enrollment. During follow-up, repeat 5T MRI may be performed optionally in participants who are willing to return for imaging reassessment. | Diagnostic test | First-Degree Relatives of Patients With Moyamoya Disease, Healthy Controls, Moyamoya Disease Patients |
Primary outcome
Incident Moyamoya Disease in First-Degree Relatives
Time frame: From enrollment through 3 years of follow-up
Incident moyamoya disease occurring during follow-up in first-degree relatives of patients with moyamoya disease, confirmed by clinical diagnosis and imaging findings, including computed tomography angiography (CTA), magnetic resonance angiography (MRA), or digital subtraction angiography (DSA).
Recurrent Stroke or Transient Ischemic Attack in Participants With Moyamoya Disease
Time frame: From enrollment through 3 years of follow-up
Occurrence of recurrent stroke or transient ischemic attack during follow-up in participants with moyamoya disease, confirmed by clinical evaluation and imaging findings when applicable.
3 secondary outcomes
Rehospitalization in Participants With Moyamoya Disease
Time frame: From enrollment through 3 years of follow-up
Repeat Surgery or Intervention in Participants With Moyamoya Disease
Time frame: From enrollment through 3 years of follow-up
Functional Outcome Assessed by Modified Rankin Scale
Time frame: At 3 years after enrollment
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Apr 2026.
- Individual participant dataSharing planned: Undecided. Individual participant data sharing is currently undecided. The study involves longitudinal clinical, imaging, biospecimen, and multi-omics data from patients with moyamoya disease, first-degree relatives, and healthy controls. Any future sharing of de-identified individual participant data will depend on institutional policy, ethics committee approval, participant consent, data privacy protection, and the development of an appropriate data access mechanism.
Related trials for Moyamoya Disease
Enrolling by invitationEarly Phase 1
Clinical Evaluation of the Safety and Efficacy of "Buyan Huan Wu Tang" Combined With Atorvastatin in the Treatment of Atypical Pneumonia
Moyamoya Disease
Recruiting
Efficacy and Safety of Ischemic Preconditioning Therapy Versus Optimal Medical Therapy in Reducing the Recurrence of Ischemic Events in Symptomatic Moyamoya Disease
Moya Moya Disease, Moyamoya Syndrome
RecruitingObservational study
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Rare Disorders, Undiagnosed Disorders
Enrolling by invitationEarly Phase 1
Clinical Safety and Efficacy Evaluation of the Blood-cooling and Stasis-removing Formula as an Adjunct to Atorvastatin in the Treatment of Hemorrhagic Moyamoya Disease.
Moyamoya Disease
RecruitingObservational study
Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome
Moyamoya Disease, Moyamoya Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Moyamoya Disease, run by Beijing Tiantan Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 8 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Dong Zhang, MD (+86-13801121292, zhangdong0660@aliyun.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incident Moyamoya Disease in First-Degree Relatives (time frame: From enrollment through 3 years of follow-up). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Apr 2026.